These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32497299)

  • 1. Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation.
    Whited LK; Handy VW; Hosing C; Chow E
    Pharmacotherapy; 2020 Aug; 40(8):773-787. PubMed ID: 32497299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
    Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
    Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
    Kindwall-Keller TL; Ballen KK
    Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Hong S; Rybicki L; Mclellan L; Dabney J; Gerds AT; Rotz SJ; Kalaycio M; Hanna R; Hamilton BK; Majhail NS; Sobecks RM
    Transplant Cell Ther; 2022 Apr; 28(4):217.e1-217.e6. PubMed ID: 35074556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatched unrelated alternative donors for hematological malignancies.
    Sebastian Schäfer H; Finke J
    Semin Hematol; 2016 Apr; 53(2):77-81. PubMed ID: 27000730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes from unrelated donor hematopoietic stem cell transplantation.
    Perez LE
    Cancer Control; 2011 Oct; 18(4):216-21. PubMed ID: 21976240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT).
    Arslan S; Al Malki MM
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):74-82. PubMed ID: 36485163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.
    Ballen K; Woo Ahn K; Chen M; Abdel-Azim H; Ahmed I; Aljurf M; Antin J; Bhatt AS; Boeckh M; Chen G; Dandoy C; George B; Laughlin MJ; Lazarus HM; MacMillan ML; Margolis DA; Marks DI; Norkin M; Rosenthal J; Saad A; Savani B; Schouten HC; Storek J; Szabolcs P; Ustun C; Verneris MR; Waller EK; Weisdorf DJ; Williams KM; Wingard JR; Wirk B; Wolfs T; Young JH; Auletta J; Komanduri KV; Lindemans C; Riches ML
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1636-1645. PubMed ID: 27343716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic hematopoietic stem cell transplantation for hematological malignancies: an algorithm for donor selection].
    Sugita J
    Rinsho Ketsueki; 2019; 60(6):626-634. PubMed ID: 31281155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies.
    El-Cheikh J; Crocchiolo R; Furst S; Bramanti S; Sarina B; Granata A; Vai A; Lemarie C; Faucher C; Mohty B; Harbi S; Bouabdallah R; Vey N; Santoro A; Chabannon C; Castagna L; Blaise D
    Cancer; 2015 Jun; 121(11):1809-16. PubMed ID: 25649994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
    Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U
    Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
    Junghanss C; Storb R; Maris MB; Carter RA; Sandmaier BM; Maloney DG; McSweeney PA; Corey L; Boeckh M
    Br J Haematol; 2003 Nov; 123(4):662-70. PubMed ID: 14616970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
    Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies].
    Yu S; Dai M; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Zhou H; Xu D; Meng F; Liu Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):826-30. PubMed ID: 25246252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.